OKYO Pharma Ltd SEC filings OKYO
OKYO Pharma Ltd has 311 filings in SEC EDGAR's recent list, going back to Mar 22, 2021. Its latest annual report, Form 20-F, was filed on Jul 20, 2026 for the period ended Mar 31, 2026. The most recent current report (Form 6-K) was filed on Nov 5, 2026.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Feb 10, 2026 | — |
| UPLOAD | Letter from the SEC | Feb 6, 2026 | — |
| CORRESP | Letter to the SEC | Feb 6, 2026 | — |
| NT 20-F | Filing | Jul 31, 2024 | Mar 31, 2024 |
| NT 20-F | Filing | Jul 31, 2023 | Mar 31, 2023 |
| EFFECT | Filing | Jun 14, 2023 | — |
| EFFECT | Filing | Jun 14, 2023 | — |
| CORRESP | Letter to the SEC | Jun 12, 2023 | — |
| CORRESP | Letter to the SEC | Jun 12, 2023 | — |
| UPLOAD | Letter from the SEC | Jun 12, 2023 | — |
| CORRESP | Letter to the SEC | Jun 2, 2023 | — |
| 8-A12B/A | Filing | Jun 2, 2023 | — |
| UPLOAD | Letter from the SEC | May 30, 2023 | — |
| EFFECT | Filing | Mar 8, 2023 | — |
| EFFECT | Filing | Feb 27, 2023 | — |
| CORRESP | Letter to the SEC | Feb 23, 2023 | — |
| CORRESP | Letter to the SEC | Feb 23, 2023 | — |
| CORRESP | Letter to the SEC | Jan 17, 2023 | — |
| CORRESP | Letter to the SEC | Jan 17, 2023 | — |
| CORRESP | Letter to the SEC | Jan 17, 2023 | — |
| RW WD | Filing | Jan 13, 2023 | — |
| CORRESP | Letter to the SEC | Jan 12, 2023 | — |
| RW | Filing | Jan 12, 2023 | — |
| CORRESP | Letter to the SEC | Jan 10, 2023 | — |
| CORRESP | Letter to the SEC | Jan 10, 2023 | — |
| CORRESP | Letter to the SEC | Jan 5, 2023 | — |
| CORRESP | Letter to the SEC | Jan 3, 2023 | — |
| CORRESP | Letter to the SEC | Jan 3, 2023 | — |
| CORRESP | Letter to the SEC | Dec 21, 2022 | — |
| CORRESP | Letter to the SEC | Dec 16, 2022 | — |
| CORRESP | Letter to the SEC | Dec 16, 2022 | — |
| UPLOAD | Letter from the SEC | Nov 22, 2022 | — |
| DRS | Filing | Nov 17, 2022 | — |
| NT 20-F | Filing | Aug 1, 2022 | Mar 31, 2022 |
| EFFECT | Filing | May 16, 2022 | — |
| EFFECT | Filing | May 16, 2022 | — |
| CORRESP | Letter to the SEC | May 12, 2022 | — |
| CORRESP | Letter to the SEC | May 12, 2022 | — |
| CORRESP | Letter to the SEC | May 12, 2022 | — |
| CERT | Filing | May 12, 2022 | — |
| 8-A12B | Filing | May 10, 2022 | — |
| CORRESP | Letter to the SEC | May 10, 2022 | — |
| CORRESP | Letter to the SEC | May 10, 2022 | — |
| CORRESP | Letter to the SEC | Mar 25, 2022 | — |
| UPLOAD | Letter from the SEC | Mar 18, 2022 | — |
| DRS/A | Filing | Nov 10, 2021 | — |
| DRSLTR | Filing | Nov 9, 2021 | — |
| UPLOAD | Letter from the SEC | Sep 8, 2021 | — |
| DRSLTR | Filing | Aug 23, 2021 | — |
| DRS | Filing | Aug 23, 2021 | — |
| UPLOAD | Letter from the SEC | Jun 7, 2021 | — |
| DRS/A | Filing | May 21, 2021 | — |
| DRSLTR | Filing | May 21, 2021 | — |
| UPLOAD | Letter from the SEC | Apr 16, 2021 | — |
| DRS | Filing | Mar 22, 2021 | — |
Showing 55 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- OKYO (Nasdaq)
- Headquarters
- London, United Kingdom
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 1849296
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.